Retatrutide 20mg

🧬 MetaboSync (Retatrutide)

MetaboSync (Retatrutide) is an investigational peptide studied for its powerful effects on metabolic regulation and obesity management. It is unique as a triple agonist, simultaneously activating GLP‑1, GIP, and glucagon receptors, which sets it apart from single or dual agonist therapies

Here’s a clinical-style product description for MetaboSync (Retatrutide), incorporating what studies have found about this investigational peptide:

---

🧬 MetaboSync (Retatrutide)

MetaboSync (Retatrutide) is an investigational peptide studied for its powerful effects on metabolic regulation and obesity management. It is unique as a triple agonist, simultaneously activating GLP‑1, GIP, and glucagon receptors, which sets it apart from single or dual agonist therapies.

---

📊 Key Findings from Studies

- Phase 2 clinical trials published in The New England Journal of Medicine showed that participants receiving the highest dose of MetaboSync (Retatrutide) achieved up to 24.2% mean weight reduction at 48 weeks, the most significant weight loss ever reported in obesity trials.  

- At 24 weeks, MetaboSync (Retatrutide) produced up to 17.5% mean weight reduction, demonstrating rapid and sustained efficacy.  

- 83% of participants on the highest dose achieved at least 15% weight loss, a threshold strongly associated with improvements in obesity-related health conditions.  

- Ongoing TRIUMPH Phase 3 trials are investigating long-term safety, durability of weight reduction, and broader metabolic outcomes.  

---

⚙️ Mechanism of Action

MetaboSync (Retatrutide) works by:

- GLP‑1 activation: Enhances insulin secretion and appetite suppression.  

- GIP activation: Improves glucose metabolism and fat utilization.  

- Glucagon activation: Increases energy expenditure and promotes fat oxidation.  

This triple pathway synergy makes MetaboSync (Retatrutide) a groundbreaking candidate in metabolic research-use 

⚠️ Compliance & Research Use

- Not FDA-approved; investigational status only.  

MetaboSync (Retatrutide) is a triple-agonist peptide studied for its unprecedented effects on weight reduction, metabolic regulation, and energy balance. In clinical trials, MetaboSync (Retatrutide) achieved up to 24.2% mean weight loss at 48 weeks, representing the most significant reduction ever reported in obesity research. Offered in a 3ml research-use vial containing 10mg lyophilized powder.

Not for human consumption. Research purposes only.